Emilia Popa, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1952368045
Payments from drug & device makers
Across 211 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$390
- AstraZeneca$371
- Boehringer Ingelheim$316
- Lilly USA, LLC$301
- Amgen$179
- Sanofi-aventis U.S. LLC$163
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,410100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $390 |
| AstraZeneca | 21 | $371 |
| Boehringer Ingelheim | 20 | $316 |
| Lilly USA, LLC | 18 | $301 |
| Amgen | 12 | $179 |
| Sanofi-aventis U.S. LLC | 10 | $163 |
| Dexcom, Inc. | 10 | $160 |
| Medtronic(2 entities) | 9 | $131 |
| Abbott | 7 | $128 |
| AbbVie | 7 | $121 |
| Tandem Diabetes Care, Inc. | 6 | $113 |
| Amneal Pharmaceuticals LLC | 6 | $111 |
| Radius Health, Inc. | 7 | $110 |
| Insulet Corporation | 7 | $102 |
| Xeris Pharmaceuticals, Inc. | 5 | $102 |
| Merck | 6 | $85 |
| IBSA Pharma Inc. | 5 | $80 |
| Pfizer | 5 | $76 |
| Shire North American Group Inc | 3 | $65 |
| Johnson & Johnson | 4 | $55 |
| Amarin Pharma, Inc. | 3 | $44 |
| Recordati_rare_diseases_inc. | 1 | $38 |
| Cequr Corporation | 3 | $33 |
| Corcept Therapeutics | 2 | $29 |
| Embecta Corp. | 1 | $28 |
| Aytu Biopharma, Inc. | 1 | $16 |
| BETA Bionics, Inc. | 1 | $16 |
| Zealand Pharma US, Inc. | 1 | $15 |
| Companion Medical, Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $13 |
| Bayer | 1 | $12 |
How this compares
$3,421 in reported general payments places this provider in the 45th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 149 | $185,731 |
| MounjaroTirzepatide | 94 | $113,380 |
| JardianceEmpagliflozin | 64 | $65,483 |
| TrulicityDulaglutide | 33 | $39,946 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $38,816 |
| FarxigaDapagliflozin Propanediol | 32 | $31,281 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $18,597 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $17,663 |
| SynthroidLevothyroxine Sodium | 165 | $14,286 |
| Humalog Kwikpen U-100Insulin Lispro | 42 | $14,015 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $13,037 |
| Novolog FlexpenInsulin Aspart | 40 | $11,986 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $11,586 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $10,507 |
| Testosterone | 17 | $6,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $390 | $185,731149 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $301 | $153,898141 claims |
| Boehringer IngelheimJardiance | $316 | $65,48364 claims |
| AstraZenecaFarxiga | $371 | $31,28132 claims |
| MerckJanumet, Janumet Xr | $85 | $28,17131 claims |
| AbbVieSynthroid | $121 | $14,286165 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $111 | $2,557294 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Julio RosenstockDallas$24.9M
- Ildiko LingvayDallas$8.2M
- Peter BresslerDallas$4.2M
- Steve FordanDallas$2.8M
- Pablo MoraDallas$2.1M
- Saleemah FahmiDallas$1.2M
- Priscilla HollanderDallas$1M
- Oksana HamidiDallas$1M
- Amy ShahDallas$953K
- Abhimanyu GargDallas$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.